Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Achim Aigner

Showing results (11-20 of 174) with videos related to

Pageof 18
Sort By:
Current Pharmaceutical Design|April 10, 2013
MicroRNAs (miRNAs) in colorectal cancer: from aberrant expression towards therapyHannelore Dassow, Achim Aigner
Nanomedicine (London, England)|December 5, 2017
Nanoparticle/siRNA-based therapy strategies in glioma: which nanoparticles, which siRNAs?Achim Aigner, Donat Kögel
Future Oncology (London, England)|February 27, 2009
Nonviral delivery platform for therapeutic RNAi: pegylated siRNA/cationic liposome complexes for targeting of the proto-oncogene bcl-2Sabrina Höbel, Achim Aigner
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 23, 2022
Therapeutic siRNA: State-of-the-Art and Future PerspectivesMaik Friedrich, Achim Aigner
Pharmaceutics|August 28, 2021
Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer TreatmentKristin Entzian, Achim Aigner
Methods in Molecular Biology (Clifton, N.J.)|March 11, 2010
Polyethylenimine (PEI)/siRNA-mediated gene knockdown in vitro and in vivoSabrina Höbel, Achim Aigner
Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology|May 31, 2013
Polyethylenimines for siRNA and miRNA delivery in vivoSabrina Höbel, Achim Aigner
Advanced Drug Delivery Reviews|March 22, 2021
Nucleic acid delivery with extracellular vesiclesMichaela Schulz-Siegmund, Achim Aigner
Deutsches Arzteblatt International|October 19, 2023
In ReplyFlorian Lordick, Maximilian Merz, Achim Aigner
International Journal of Cancer|April 15, 2014
Multiple effects of the special AT-rich binding protein 1 (SATB1) in colon carcinomaAnja Frömberg, Michael Rabe, Achim Aigner
Pageof 18

Showing results (11-20 of 174) with videos related to

Sort By:
Pageof 18
Current Pharmaceutical Design|April 10, 2013
MicroRNAs (miRNAs) in colorectal cancer: from aberrant expression towards therapyHannelore Dassow, Achim Aigner
Nanomedicine (London, England)|December 5, 2017
Nanoparticle/siRNA-based therapy strategies in glioma: which nanoparticles, which siRNAs?Achim Aigner, Donat Kögel
Future Oncology (London, England)|February 27, 2009
Nonviral delivery platform for therapeutic RNAi: pegylated siRNA/cationic liposome complexes for targeting of the proto-oncogene bcl-2Sabrina Höbel, Achim Aigner
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 23, 2022
Therapeutic siRNA: State-of-the-Art and Future PerspectivesMaik Friedrich, Achim Aigner
Pharmaceutics|August 28, 2021
Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer TreatmentKristin Entzian, Achim Aigner
Methods in Molecular Biology (Clifton, N.J.)|March 11, 2010
Polyethylenimine (PEI)/siRNA-mediated gene knockdown in vitro and in vivoSabrina Höbel, Achim Aigner
Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology|May 31, 2013
Polyethylenimines for siRNA and miRNA delivery in vivoSabrina Höbel, Achim Aigner
Advanced Drug Delivery Reviews|March 22, 2021
Nucleic acid delivery with extracellular vesiclesMichaela Schulz-Siegmund, Achim Aigner
Deutsches Arzteblatt International|October 19, 2023
In ReplyFlorian Lordick, Maximilian Merz, Achim Aigner
International Journal of Cancer|April 15, 2014
Multiple effects of the special AT-rich binding protein 1 (SATB1) in colon carcinomaAnja Frömberg, Michael Rabe, Achim Aigner
Pageof 18